Showing 5491-5500 of 9312 results for "".
- ACS Study: Skin Creams Aren’t What We Thought They Werehttps://practicaldermatology.com/news/acs-study-skin-creams-arent-what-we-thought-they-were/2460136/Researchers report the first direct glimpse of how a skin cream or lotion is structured on the molecular scale, and it’s not quite what they expected. They presented their results at the American Chemical Society (ACS) Fall 2019 National Meeting & Exposition in San Diego.
- Amgen To Acquire Otezla® For $13.4 Billion In Cashhttps://practicaldermatology.com/news/amgen-to-acquire-otezla-for-134-billion-in-cash/2460135/Amgen has entered into an agreement with Celgene Corporation in connection with its previously announced merger with Bristol-Myers Squibb Company </
- Lilly’s Oral JAK Inhibitor Plus Steroids Improves AD Symptomshttps://practicaldermatology.com/news/lillys-oral-jak-inhibitor-plus-steroids-improves-ad-symptoms/2460134/Adding the oral JAK inhibitor baricitinib to standard-of-care topical corticosteroids significantly improved atopic dermatitis disease severity, measured by the validated Investigator's Global Assessment for AD (vIGA) score of "clear or almost clear" skin (vIGA 0, 1), the primary en
- ASDS 2018 Survey: Skin Cancer Treatments and Cosmetic Procedures are on the Risehttps://practicaldermatology.com/news/asds-2018-survey-skin-cancer-treatments-and-cosmetic-procedures-are-on-the-rise/2460133/American Society for Dermatologic Surgery (ASDS) member dermatologists performed more than 12.5 million medical and cosmetic procedures in 2018 – 7.5 percent more than 2017 and a 60 percent increase since 2012, according to the 2018 ASDS
- Cassiopea Submits NDA for New Acne Treatmenthttps://practicaldermatology.com/news/cassiopea-submits-nda-for-new-acne-treatment/2460131/Cassiopea SpA submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking marketing approval for clascoterone cream 1% for the treatment of acne. Clascoterone cream 1% is under investigation as a first-in-class topical androgen receptor inhibitor for th
- Straight Up: Paula Abdul Is InMode's New Brand Ambassadorhttps://practicaldermatology.com/news/straight-up-paula-abdul-is-inmodes-new-brand-ambassador/2460122/Paula Abdul is InMode’s new brand ambassador for BodyTite, FaceTite and Morpheus8 technologies. As a lifelong performer, Abdul has always taken care of herself and has the muscles to prove it—however, at age 57, she acknowledg
- Ortho Derm Gets NDA for IDP-123 Lotion for Acnehttps://practicaldermatology.com/news/ortho-derm-gets-nda-for-idp-123-lotion-for-acne-1/2460121/The U.S. Food and Drug Administration (FDA) has accepted Ortho Dermatologic’s New Drug Application for IDP-123 (tazarotene 0.045%) Lotion or acne with a PDUFA action date of Dec. 22, 2019. If approved, IDP-123 will be the first taza
- PE in Dermatology: NavaDerm Partners with Laser & Skin Surgery Center of NYhttps://practicaldermatology.com/news/pe-in-dermatology-navaderm-partners-with-laser-skin-surgery-center-of-ny/2460119/NavaDerm is partnering with Laser & Skin Surgery Center of New York, Midtown Dermatology and their affiliated entities. Navaderm is a dermatology services organization in the Northeast and a BelHealth Investm
- Ortho Dermatologics Expands Cash-Pay Prescription Program with Walgreens Agreementhttps://practicaldermatology.com/news/ortho-dermatologics-expands-cash-pay-prescription-program-with-walgreens-agreement/2460115/Ortho Dermatologics’ Cash-Pay Prescription Plan is now available at Walgreen’s stores nationwide. Under the expanded agreement, Walgreens patients will have access to the select dermatology products included in Ortho Dermatologics’ first-of-its-kind cash-pay pres
- New AAD, NPF Guidelines Address Psoriasis Phototherapyhttps://practicaldermatology.com/news/new-aad-npf-guidelines-address-psoriasis-phototherapy/2460109/New guidelines from the American Academy of Dermatology (AAD) and the National Psoriasis Foundation (NPF) take on psoriasis phototherapy. The